Brazil top court gives nod for probe into Bolsonaro over vaccine deal
Reuters
Published Jul 03, 2021 11:12AM ET
SAO PAULO (Reuters) - Brazil's Supreme Court Justice Rosa Weber late on Friday authorized an investigation of President Jair Bolsonaro by the top prosecutor's office, or PGR, for dereliction of duty in the process of procuring an Indian COVID-19 vaccine, according to a copy of the decision seen by Reuters.
The president has been implicated in allegations of irregularities surrounding a 1.6 billion reais ($316 million) contract signed in February for 20 million doses with a Brazilian intermediary for the vaccine's maker, Bharat Biotech.
A Brazilian Senate commission investigating the administration's handling of the pandemic has cited suspicions of overpricing and corruption related to the contract. After allegations of irregularities surfaced, the government suspended the contract.
Brazil has suffered the world's second highest number of COVID-19 deaths.
Brazilian federal prosecutors and the comptroller general's office, or CGU, are also separately investigating the alleged irregularities in the deal. The case allegedly involves the government's chief whip in the lower house of Congress, Ricardo Barros, according to lawmakers.
Bolsonaro and Barros denied any wrongdoing.
The investigation of the president by the PGR had to be formally authorized by the Supreme Court. In her decision, Justice Weber gave authorities 90 days for collection of evidence pertaining to the case.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.